Arvinas, Inc. (ARVN): Capital Expenditures
$1.90M
Year ended 2025-12-31
$1.80M
Trailing 12 months to 2026-06-30
-34.6%
3-year compound annual growth
-21.6%
5-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.90M | +5.6% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $1.80M | -37.9% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $2.90M | -57.4% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $6.80M | +44.7% | 2025-02-11, From 2022-01-01 |
| 2021-12-31 | $4.70M | -26.6% | 2024-02-27, From 2021-01-01 |
| 2020-12-31 | $6.40M | +1.6% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $6.30M | +122.6% | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | $2.83M | +179.6% | 2021-03-01, From 2018-01-01 |
| 2017-12-31 | $1.01M | n/a | 2019-03-26, From 2017-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Arvinas, Inc. (ARVN) | 2025-12-31 | $1.90M | +5.6% |
| Ligand Pharmaceuticals Inc (LGND) | 2025-12-31 | $452.0K | -75.2% |
| Vireo Growth Inc. (VREOF) | 2025-12-31 | $28.32M | +142.2% |
| Schrodinger, Inc. (SDGR) | 2025-12-31 | $1.44M | -80.3% |
| Harrow, Inc. (HROW) | 2025-12-31 | $887.0K | -44.4% |
| Arcus Biosciences, Inc. (RCUS) | 2025-12-31 | $2.00M | -66.7% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $1.55M | -19.7% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $291.0K | +781.8% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $87.0K | -75.7% |
Compare ARVN, LGND, VREOF, SDGR side by side · Screen every company in Pharmaceutical Preparations ↗